Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
March 5, 2025 McKemey joins Certara to accelerate growth of its strategic drug development solutions …
CertaraMarch 5, 2025
Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach
This study explores a model-based meta-analysis (MBMA) and a clinical utility index (CUI) approach to…
CertaraMarch 4, 2025
Machine Learning for PK/PD Modeling in Drug Development
Pharmacometricians can use machine learning for PK/PD modeling to help them characterize the safety and…
CertaraMarch 4, 2025
CDISC data standards – Beyond value [Korean Webinar]
March 13, 2025 - 3:00 pm Korea
CertaraMarch 3, 2025
Comparison Across Anti-PD-1 Antibodies – Insights From QSP-Based Meta-Analysis
Regulatory-ready systems modeling software to optimize drug developmentDiscover how Certara’s QSP Software can accelerate your…
CertaraMarch 2, 2025
